NEW YORK (GenomeWeb News) – Pressure Biosciences said today that it has struck a co-marketing and distribution pact with UK-based Constant Systems that will enable the companies to offer each other's products in North America and Europe.

Under the agreement, Pressure Bio will receive non-exclusive rights to market, sell, and distribute CS's high-pressure cell disruption equipment and consumables in the US, Canada, and Mexico.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.